Royce Johnson1,2, Jackie Ho3, Pete Fowler4, Arash Heidari1,2. 1. David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. 2. Division of Infectious Disease, Valley Fever Institute, Kern Medical, Bakersfield, CA, USA. 3. Department of Pharmacy, San Leandro Hospital, 13855 E 14th St, San Leandro, CA, 94578, USA. jackie.ho@tu.edu. 4. Department of Pharmacy, Kaiser Permanente, Oakland, CA, USA.
Abstract
PURPOSE OF REVIEW: This article summarizes the diagnosis and treatment of coccidioidal meningitis (CM) and its complications. An overview of current and prospective pharmacologic treatment options and monitoring parameters is provided. A consensus has not been reached regarding universally accepted therapeutic serum levels for azoles because of insufficient evidence. We describe the preferred therapeutic drug level ranges that our institution uses to monitor azole therapy. RECENT FINDINGS: Ho et al. described the preparation and administration of intrathecally delivered amphotericin B deoxycholate. Thompson et al. described possible benefits of controversial adjuvant corticosteroid therapy for secondary prevention of vasculitic infarction secondary to CM. CM was universally fatal until the advent of intrathecal amphotericin B deoxycholate therapy, the introduction of which changed the natural history of the disease in much the same way as penicillin changed the natural history of bacterial meningitis. Although there was still significant morbidity, survival rates drastically increased to approximately 70%. The introduction of azole therapy has decreased the side effects and burden of treatment but without a significant change in CM-related mortality and morbidity compared with the use of intrathecal amphotericin B deoxycholate therapy.
PURPOSE OF REVIEW: This article summarizes the diagnosis and treatment of coccidioidal meningitis (CM) and its complications. An overview of current and prospective pharmacologic treatment options and monitoring parameters is provided. A consensus has not been reached regarding universally accepted therapeutic serum levels for azoles because of insufficient evidence. We describe the preferred therapeutic drug level ranges that our institution uses to monitor azole therapy. RECENT FINDINGS: Ho et al. described the preparation and administration of intrathecally delivered amphotericin B deoxycholate. Thompson et al. described possible benefits of controversial adjuvant corticosteroid therapy for secondary prevention of vasculitic infarction secondary to CM. CM was universally fatal until the advent of intrathecal amphotericin B deoxycholate therapy, the introduction of which changed the natural history of the disease in much the same way as penicillin changed the natural history of bacterial meningitis. Although there was still significant morbidity, survival rates drastically increased to approximately 70%. The introduction of azole therapy has decreased the side effects and burden of treatment but without a significant change in CM-related mortality and morbidity compared with the use of intrathecal amphotericin B deoxycholate therapy.
Authors: Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson Journal: Clin Infect Dis Date: 2008-02-01 Impact factor: 9.079
Authors: Robert S Bercovitch; Antonino Catanzaro; Brian S Schwartz; Demosthenes Pappagianis; D Heather Watts; Neil M Ampel Journal: Clin Infect Dis Date: 2011-08 Impact factor: 9.079
Authors: David A Stevens; Adrian Rendon; Veronica Gaona-Flores; Antonino Catanzaro; Gregory M Anstead; Lisa Pedicone; J Richard Graybill Journal: Chest Date: 2007-06-15 Impact factor: 9.410
Authors: John R Perfect; William E Dismukes; Francoise Dromer; David L Goldman; John R Graybill; Richard J Hamill; Thomas S Harrison; Robert A Larsen; Olivier Lortholary; Minh-Hong Nguyen; Peter G Pappas; William G Powderly; Nina Singh; Jack D Sobel; Tania C Sorrell Journal: Clin Infect Dis Date: 2010-02-01 Impact factor: 9.079
Authors: George R Thompson; Adrian Rendon; Rodrigo Ribeiro Dos Santos; Flavio Queiroz-Telles; Luis Ostrosky-Zeichner; Nkechi Azie; Rochelle Maher; Misun Lee; Laura Kovanda; Marc Engelhardt; Jose A Vazquez; Oliver A Cornely; John R Perfect Journal: Clin Infect Dis Date: 2016-05-11 Impact factor: 9.079
Authors: María F De la Cerda-Vargas; B A Sandoval-Bonilla; James M McCarty; Fernando Chico-Ponce De León; José A Candelas-Rangel; Jorge D Rodríguez-Rodríguez; Pedro Navarro-Domínguez; Melisa A Muñoz-Hernández; Elizabeth Meza-Mata; Elena M Fernández-González; Mariana G Sámano-Aviña Journal: Surg Neurol Int Date: 2021-03-24